BridgeBio Oncology Therapeutics (BBOT) Liabilities and Shareholders Equity (2023 - 2026)

BridgeBio Oncology Therapeutics has reported Liabilities and Shareholders Equity for 4 years, with the latest figure at $417.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 113.44% year-over-year to $417.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 108.6% YoY) and the FY2025 annual result came in at $448.4 million, up 172.9% from the prior year.
• Liabilities and Shareholders Equity fell to $417.6 million in Q1 2026 per BBOT's latest filing, from $448.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $484.8 million in Q3 2025 and troughed at $332894.0 in Q4 2023.
• A 4-year average of $247.8 million and a median of $194.0 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity soared 49255.35% in 2024, then gained 3.96% in 2025.
• Over 4 years, Liabilities and Shareholders Equity stood at $332894.0 in 2023, then jumped by 49255.35% to $164.3 million in 2024, then soared by 172.9% to $448.4 million in 2025, then fell by 6.85% to $417.6 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $417.6 million, $448.4 million, and $484.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.